{"id":16760,"date":"2020-09-03T08:29:44","date_gmt":"2020-09-03T12:29:44","guid":{"rendered":"https:\/\/medicarereport.org\/?p=16760"},"modified":"2020-09-03T08:29:44","modified_gmt":"2020-09-03T12:29:44","slug":"drug-combination-slows-progression-of-als-and-could-mark-new-era-in-treatment","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=16760","title":{"rendered":"Drug Combination Slows Progression Of ALS And Could Mark &#8216;New Era&#8217; In Treatment"},"content":{"rendered":"<p>(By Jon Hamilton for NPR)<\/p>\n<p>A combination of two experimental drugs appears to slow the decline of patients with amyotrophic lateral sclerosis, an illness often known as ALS or Lou Gehrig&#8217;s disease.<\/p>\n<p>A six-month study of 137 patients with a fast-progressing form of the disease found that those who got daily doses of a two-drug combination called AMX0035 scored several points higher on a standard measure of function, a team\u00a0reports\u00a0in the Sept. 3 issue of\u00a0The New England Journal of Medicine.\u00a0 Continue reading article <a href=\"https:\/\/www.npr.org\/sections\/health-shots\/2020\/09\/02\/908874110\/drug-combination-slows-progression-of-als-and-could-mark-new-era-in-treatment\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-3902\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\" alt=\"\" width=\"152\" height=\"55\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png 152w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo-150x55.png 150w\" sizes=\"auto, (max-width: 152px) 100vw, 152px\" \/><\/a><\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Jon Hamilton for NPR) A combination of two experimental drugs appears to slow the decline of patients with amyotrophic<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,15],"tags":[],"class_list":["post-16760","post","type-post","status-publish","format-standard","hentry","category-health-care-general","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/16760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16760"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/16760\/revisions"}],"predecessor-version":[{"id":16761,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/16760\/revisions\/16761"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}